BioWorld always honors news embargoes. An early heads up gives us extra time to prepare and conduct research. We promise to keep your news confidential until the stated embargo lifts. BioWorld is the ...

Scientists in Europe have added their voices to the many thousands of objections made against proposed changes to the ...

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in ...

Investigators at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have demonstrated that in the ...

U.K. biotech has recorded the strongest quarter for venture capital raised in five years, with companies attracting £2.05 billion (US$3.36 billion) in the second quarter (Q2) of 2026. While that ...

New hires and promotions in the biopharma and med-tech industries, including: Gyre, Niagen.

Immix Biopharma Inc.’s shares (NASDAQ:IMMX) sank 14% to $8.80 on July 20 after investors learned that a man named Richard Graydon, who served as its chief medical officer, was in fact a 20-year ...

Rinascera Therapeutics Inc. has secured enough initial funding to acquire two drugs for rare genetic skin diseases, despite ...

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Cellution, Dimerix, Elutia, IPG, Jasper, Kira, Lumibird, Medtronic, Mission, Red Light Holland, SPR.

AMT Medical BV reported positive one-year data from a study looking at its ELANA device, a sutureless coronary bypass technology designed to simplify one of the most technically demanding steps in ...

Biopharma and med-tech companies raising money in public or private financings, including: Blossomhill, Crescent, Endo Tools, Regenxbio, Trellis.

On the tail of rumors that Merck & Co. Inc. and others holding stakes in Personalis Inc. might take over the firm, Chicago-based Tempus AI Inc. ended speculation by disclosing its plan to buy the ...